GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bolt Biotherapeutics Inc (FRA:6LP) » Definitions » Debt-to-Revenue

Bolt Biotherapeutics (FRA:6LP) Debt-to-Revenue : 0.93 (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Bolt Biotherapeutics Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Bolt Biotherapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €2.66 Mil. Bolt Biotherapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €15.35 Mil. Bolt Biotherapeutics's annualized Revenue for the quarter that ended in Mar. 2024 was €19.41 Mil. Bolt Biotherapeutics's annualized Debt-to-Revenue for the quarter that ended in Mar. 2024 was 0.93.


Bolt Biotherapeutics Debt-to-Revenue Historical Data

The historical data trend for Bolt Biotherapeutics's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bolt Biotherapeutics Debt-to-Revenue Chart

Bolt Biotherapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Revenue
Get a 7-Day Free Trial 47.25 47.06 19.33 3.95 2.57

Bolt Biotherapeutics Quarterly Data
Dec18 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.02 3.75 2.06 2.42 0.93

Competitive Comparison of Bolt Biotherapeutics's Debt-to-Revenue

For the Biotechnology subindustry, Bolt Biotherapeutics's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bolt Biotherapeutics's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bolt Biotherapeutics's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Bolt Biotherapeutics's Debt-to-Revenue falls into.



Bolt Biotherapeutics Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Bolt Biotherapeutics's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(2.551 + 15.99) / 7.222
=2.57

Bolt Biotherapeutics's annualized Debt-to-Revenue for the quarter that ended in Mar. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(2.656 + 15.346) / 19.408
=0.93

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Mar. 2024) Revenue data.


Bolt Biotherapeutics Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Bolt Biotherapeutics's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Bolt Biotherapeutics (FRA:6LP) Business Description

Traded in Other Exchanges
Address
900 Chesapeake Drive, Redwood, CA, USA, 94063
Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems.

Bolt Biotherapeutics (FRA:6LP) Headlines

No Headlines